Flossbach Von Storch AG boosted its position in Becton Dickinson and Co (NYSE:BDX) by 334.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,875,063 shares of the medical instruments supplier’s stock after acquiring an additional 1,443,558 shares during the quarter. Becton Dickinson and accounts for 2.9% of Flossbach Von Storch AG’s holdings, making the stock its 12th largest holding. Flossbach Von Storch AG owned 0.69% of Becton Dickinson and worth $430,833,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Klingenstein Fields & Co. LLC increased its stake in Becton Dickinson and by 1.3% in the fourth quarter. Klingenstein Fields & Co. LLC now owns 3,038 shares of the medical instruments supplier’s stock valued at $826,000 after acquiring an additional 38 shares during the last quarter. Smith Shellnut Wilson LLC ADV lifted its holdings in shares of Becton Dickinson and by 3.2% during the first quarter. Smith Shellnut Wilson LLC ADV now owns 1,305 shares of the medical instruments supplier’s stock worth $300,000 after purchasing an additional 40 shares during the period. TrinityPoint Wealth LLC lifted its holdings in shares of Becton Dickinson and by 1.8% during the fourth quarter. TrinityPoint Wealth LLC now owns 2,505 shares of the medical instruments supplier’s stock worth $681,000 after purchasing an additional 45 shares during the period. Unified Trust Company N.A. lifted its holdings in shares of Becton Dickinson and by 0.5% during the fourth quarter. Unified Trust Company N.A. now owns 10,189 shares of the medical instruments supplier’s stock worth $2,771,000 after purchasing an additional 47 shares during the period. Finally, Lido Advisors LLC lifted its holdings in shares of Becton Dickinson and by 1.4% during the fourth quarter. Lido Advisors LLC now owns 3,477 shares of the medical instruments supplier’s stock worth $946,000 after purchasing an additional 47 shares during the period. 86.79% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE BDX traded up $0.31 during trading on Friday, hitting $239.25. 11,783,270 shares of the company traded hands, compared to its average volume of 1,932,654. The business’s fifty day moving average is $253.35 and its 200 day moving average is $255.35. Becton Dickinson and Co has a fifty-two week low of $197.75 and a fifty-two week high of $286.72. The firm has a market capitalization of $64.79 billion, a price-to-earnings ratio of 72.06, a P/E/G ratio of 2.57 and a beta of 0.95. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.23. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The firm had revenue of $4.25 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the business earned $2.59 earnings per share. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and Co will post 10.5 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.32%. Becton Dickinson and’s dividend payout ratio is currently 27.05%.
A number of equities analysts have recently commented on BDX shares. Barclays reiterated a “hold” rating and set a $266.00 price target on shares of Becton Dickinson and in a report on Tuesday, April 14th. Wells Fargo & Co restated a “buy” rating on shares of Becton Dickinson and in a report on Friday, May 8th. Citigroup boosted their target price on shares of Becton Dickinson and from $234.00 to $260.00 and gave the company a “neutral” rating in a report on Friday, May 8th. TheStreet lowered shares of Becton Dickinson and from a “b” rating to a “c+” rating in a report on Monday, March 9th. Finally, Piper Sandler boosted their target price on shares of Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $275.79.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Trade War
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.